Technology Exchange Combines Unique Methods for Design of Novel, High Quality Compounds in Drug Discovery

Innovative software and services provider Cresset, and Optibrium, a provider of software solutions for drug discovery, announce an agreement to collaborate on the development of next-generation platforms. The innovative companies will work together, combining unique approaches to help drug discovery projects quickly identify novel, potent compounds with a high chance of success downstream. The collaboration will involve a two-way exchange of technologies: Optibrium’s ADME models, currently provided as a plug-in module for its StarDrop™ software platform, will be made available to users of Cresset’s desktop applications. Similarly, Cresset’s FieldAlignTM software, which helps chemists understand the three-dimensional structure-activity-relationship of their chemistry in order to design active compounds, will be made available as an optional plug-in module for StarDrop, which helps project teams to confidently target compounds with a good balance of properties for their therapeutic objectives.

Achieving a combination of potency with appropriate ADME and safety properties is essential to the discovery of high quality drug candidates. Cresset’s molecular field technology provides unique insight into the biological activity, properties and interactions of molecules, which enables biologically meaningful comparisons that are not limited by two-dimensional structure. Optibrium’s StarDrop platform helps to guide decisions on the design and selection of compounds by integrating in silico and experimentally measured properties using a unique multi-parameter  optimisation approach, chemical space and Glowing Molecule™ visualisations and predictive modelling.

The technology shared under this collaboration will form new components in upcoming releases of Optibrium's StarDrop and Cresset's desktop applications.